Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis.
Iain B McInnesProton RahmanAlice B GottliebElizabeth C HsiaAlexa P KollmeierXie L XuYusang JiangShihong ShengMay ShawiSoumya D ChakravartyDésirée van der HeijdePhillip J MeasePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
In biologic-naïve PsA patients, guselkumab provided durable improvements in multiple disease domains with no unexpected safety findings through 2years.